CN105641680A - Oritavancin pharmaceutical composition and preparation method thereof - Google Patents
Oritavancin pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN105641680A CN105641680A CN201410633934.9A CN201410633934A CN105641680A CN 105641680 A CN105641680 A CN 105641680A CN 201410633934 A CN201410633934 A CN 201410633934A CN 105641680 A CN105641680 A CN 105641680A
- Authority
- CN
- China
- Prior art keywords
- oritavancin
- pharmaceutical composition
- microcrystalline cellulose
- pregelatinized starch
- polyvinylpolypyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses an oritavancin pharmaceutical composition, which contains oritavancin, a disintegrating agent, microcrystalline cellulose and pre-gelatinized starch, and is characterized in that a weight ratio of the microcrystalline cellulose to the pre-gelatinized starch is 1-1.5. According to the present invention, the oritavancin pharmaceutical composition has good stability, provides significant advantages for product yield improving, cost reducing, industrialization achievement and good clinical application, and further has advantages of effectively-improved dissolution and significantly improved bioavailability.
Description
Technical field
The invention belongs to pharmaceutical technology field, be specifically related to oritavancin pharmaceutical composition and preparation method thereof.
Background technology
Oritavancin (oritavancin, Orbactiv, IV) it is a LG antimicrobial drug, on August 6th, 2014, FDA approved oritavancin injection, treatment for the acute bacterial skin caused by sensitive gram positive bacteria (including methicillin-resistant staphylococcus aureus, MRSA) and skin structure infection (ABSSSIs) adult patient.
Its structural formula is:
The present inventor is through the research to prior art, have been surprisingly found that, apply special adjuvant, oritavancin pharmaceutical composition prepared by special process, reliable in quality, dissolution rate is fast, not only successfully solve the problem that oritavancin is unstable, and be prone to industrialization, reduce production cost, easy to implement, remarkable in economical benefits.
Summary of the invention
The first object of the present invention is in that to provide a kind of oritavancin pharmaceutical composition, and this oritavancin pharmaceutical composition, to good stability, to improving product yield, reduces cost, it is achieved industrialization, is better applied to clinic, has more obvious advantage.
The second object of the present invention is in that the preparation method providing oritavancin pharmaceutical composition of the present invention, and the method is simple, and prepared oritavancin pharmaceutical composition, steady quality is reliable.
For realizing the first object of the present invention, present inventors have surprisingly found that the pharmaceutical composition of a kind of oritavancin, said composition contains oritavancin, disintegrating agent, microcrystalline Cellulose and pregelatinized Starch, it is characterised in that the weight ratio of microcrystalline Cellulose and pregelatinized Starch is 1-1.5.
Specifically, the present invention containing the pharmaceutical composition of oritavancin, component and percentage by weight that it contains be:
Oritavancin 10-15%
Disintegrating agent 4-6%
Microcrystalline Cellulose 30-45%
Pregelatinized Starch 30-37.5%
Wherein, described disintegrating agent is selected from polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose or one or more in CCMS-Na. Preferred disintegrating agent is selected from polyvinylpolypyrrolidone.
Microcrystalline Cellulose and pregelatinized Starch are the filleies of the present invention, can contain appropriate lubricant as required, for instance can contain one or both the mixture in appropriate micropowder silica gel or magnesium stearate.
The preparation method of the pharmaceutical composition more than containing oritavancin is: the adjuvant taking oritavancin and formula ratio is pulverized, and sieves for subsequent use; Oritavancin is mixed homogeneously with adjuvant mixture; Measure mixture content of dispersion, calculate tablet weight, tabletting, coating and get final product.
One of preferred version of the present invention is:
Oritavancin 10%
Polyvinylpolypyrrolidone 6%
Microcrystalline Cellulose 40%
Pregelatinized Starch 35%
Magnesium stearate 4.5%
Micropowder silica gel 4.5%
Another preferred scheme of the present invention is:
Oritavancin 15%
Polyvinylpolypyrrolidone 6%
Microcrystalline Cellulose 45%
Pregelatinized Starch 30%
Magnesium stearate 2%
Micropowder silica gel 2%
The concrete preparation method of above-mentioned oritavancin pharmaceutical composition comprises the steps:
1)Prepare: polyvinylpolypyrrolidone, pregelatinized Starch, microcrystalline Cellulose, magnesium stearate and micropowder silica gel are dried 4 hours under 80 DEG C of conditions, standby;
2)By the pregelatinized Starch of recipe quantity, microcrystalline Cellulose and oritavancin, put in container, after mix homogeneously, be ground to granularity at 80 �� 10um, standby;
3)By 2) item mixs homogeneously with the polyvinylpolypyrrolidone of recipe quantity, magnesium stearate and micropowder silica gel;
4)Tabletting: regulate suitable stiff and tablet weight, carry out tabletting;
5) coating: with 70% ethanol, the film coating agent of recipe quantity is configured to the solution that content is 10%, regulates coating pan rotating speed, inlet temperature, pressure, carries out coating;
6)Packaging: adopt aluminium-plastic bubble plate packing machine to pack;
7)Warehouse-in.
On the basis of existing pharmaceutical adjunct and preparation technology, the present inventor finds through substantial amounts of experimental study, filler is selected, find two kinds of necessary proportion relations of filler, when to make oritavancin pharmaceutical composition be above-mentioned formula and preparation technology, described pharmaceutical composition quality is effectively ensured.
Compared with prior art, present invention have the advantage that
1) oritavancin pharmaceutical composition provided by the present invention is for improving the yield of this product, reducing production cost, and being better applied to clinical treatment has very big help.
2) new oritavancin compositions provided by the present invention is through industrialized great production and study on the stability, it was demonstrated that constant product quality.
3) preparation method of new oritavancin compositions provided by the present invention, the method is simple, prepared oritavancin pharmaceutical composition reliable in quality.
4) new oritavancin compositions provided by the present invention, dissolution is fast, has higher bioavailability, is rapidly reached and needs concentration.
Detailed description of the invention
Following example are only used for explaining the present invention rather than the restriction present invention. Unless otherwise indicated, the experiment condition in the embodiment of the present invention is the experiment condition that this area is conventional.
Embodiment 1
Every 1000 described oritavancin pharmaceutical compositions, its formula consists of:
Oritavancin 40g
Polyvinylpolypyrrolidone 12g
Microcrystalline Cellulose 70g
Pregelatinized Starch 70g
Magnesium stearate 4g
Micropowder silica gel 4g
Preparation technology:
1)Prepare: polyvinylpolypyrrolidone, pregelatinized Starch, microcrystalline Cellulose, magnesium stearate and micropowder silica gel are dried 4 hours under 80 DEG C of conditions, standby;
2)By the pregelatinized Starch of recipe quantity, microcrystalline Cellulose and oritavancin, put in container, after mix homogeneously, be ground to granularity at 80 �� 10um, standby;
3)By 2) item mixs homogeneously with the polyvinylpolypyrrolidone of recipe quantity, magnesium stearate and micropowder silica gel;
4)Tabletting: regulate suitable stiff and tablet weight, carry out tabletting;
5) coating: with 70% ethanol, the film coating agent of recipe quantity is configured to the solution that content is 10%, regulates coating pan rotating speed, inlet temperature, pressure, carries out coating;
6)Packaging: adopt aluminium-plastic bubble plate packing machine to pack;
7)Warehouse-in.
Embodiment 2
Every 1000 described oritavancin pharmaceutical compositions, its formula consists of:
Oritavancin 80g
Polyvinylpolypyrrolidone 24g
Microcrystalline Cellulose 140g
Pregelatinized Starch 140g
Magnesium stearate 8g
Micropowder silica gel 8g
Preparation technology: with embodiment 1.
Embodiment 3
Every 1000 described oritavancin pharmaceutical compositions, its formula consists of:
Oritavancin 40g
Polyvinylpolypyrrolidone 16g
Microcrystalline Cellulose 120g
Pregelatinized Starch 80g
Magnesium stearate 5.3g
Micropowder silica gel 5.3g
Preparation technology: with embodiment 1.
Test example 1
This test example is in that to investigate the stability of oritavancin compositions provided by the present invention.
The accelerated test of oritavancin pharmaceutical composition
Preparing oritavancin pharmaceutical composition according to the method for embodiment of the present invention 1-3, at 40 DEG C �� 2 DEG C, the condition of RH75% �� 5% is placed 6 months, period respectively at the 1st, 2,3, sampling in 6 months, survey according to stability check item visual inspection, and compare with 0 day data.
1, project is investigated
High spot reviews: character, have related substance and content.
2, accelerated test result
Above conclusion (of pressure testing) is it can be seen that embodiments of the invention 1-3 places 6 months every Testing index when accelerated test and compares no significant difference, good stability in 0 month, and impurity content is few, has good dissolution simultaneously.
Test example 2
Adopt 2010 editions annex XC dissolution method the second method (slurry processes) 75rpm of Chinese Pharmacopoeia. Using the Ph4.5 acetate buffer 900mL containing 0.2%SDS as dissolution medium, the stripping curve of the tablet of the detection embodiment of the present invention 1 and embodiment 3 preparation, result is as follows:
Testing result illustrates, the sample adopting the method for the present invention to prepare, and has quick dissolution rate.
Claims (7)
1. an oritavancin pharmaceutical composition, said composition contains oritavancin, disintegrating agent, microcrystalline Cellulose and pregelatinized Starch, it is characterised in that the weight ratio of microcrystalline Cellulose and pregelatinized Starch is 1-1.5.
2. oritavancin pharmaceutical composition according to claim 1, it is characterised in that the percentage by weight of described each component is:
Oritavancin 15-25%
Disintegrating agent 4-6%
Microcrystalline Cellulose 30-45%
Pregelatinized Starch 30-37.5%.
3. oritavancin pharmaceutical composition according to claim 1 and 2, it is characterised in that described disintegrating agent is selected from polyvinylpolypyrrolidone.
4. oritavancin pharmaceutical composition according to claim 3, it is characterised in that possibly together with one or both in magnesium stearate or micropowder silica gel.
5. oritavancin pharmaceutical composition according to claim 4, it is characterised in that described component and percentage by weight be:
Oritavancin 20%
Polyvinylpolypyrrolidone 6%
Microcrystalline Cellulose 35%
Pregelatinized Starch 35%
Magnesium stearate 2%
Micropowder silica gel 2%.
6. oritavancin pharmaceutical composition according to claim 4, it is characterised in that described component and percentage by weight be:
Oritavancin 15%
Polyvinylpolypyrrolidone 6%
Microcrystalline Cellulose 45%
Pregelatinized Starch 30%
Magnesium stearate 2%
Micropowder silica gel 2%.
7. a preparation method for the oritavancin pharmaceutical composition according to claim 4-6 any one, the method comprises the steps:
1)Prepare: polyvinylpolypyrrolidone, pregelatinized Starch, microcrystalline Cellulose, magnesium stearate and micropowder silica gel are dried 4 hours under 80 DEG C of conditions, standby;
2)By the pregelatinized Starch of recipe quantity, microcrystalline Cellulose and oritavancin, put in container, after mix homogeneously, be ground to granularity at 80 �� 10um, standby;
3)By 2) item mixs homogeneously with the polyvinylpolypyrrolidone of recipe quantity, magnesium stearate and micropowder silica gel;
4)Tabletting: regulate suitable stiff and tablet weight, carry out tabletting;
5) coating: with 70% ethanol, the film coating agent of recipe quantity is configured to the solution that content is 10%, regulates coating pan rotating speed, inlet temperature, pressure, carries out coating;
6)Packaging: adopt aluminium-plastic bubble plate packing machine to pack;
7)Warehouse-in.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410633934.9A CN105641680A (en) | 2014-11-12 | 2014-11-12 | Oritavancin pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410633934.9A CN105641680A (en) | 2014-11-12 | 2014-11-12 | Oritavancin pharmaceutical composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105641680A true CN105641680A (en) | 2016-06-08 |
Family
ID=56483246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410633934.9A Pending CN105641680A (en) | 2014-11-12 | 2014-11-12 | Oritavancin pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105641680A (en) |
-
2014
- 2014-11-12 CN CN201410633934.9A patent/CN105641680A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104288154A (en) | Favipiravir pharmaceutical composition containing different particle size ranges | |
| CN105193752A (en) | Vildagliptin tablet and preparation method thereof | |
| CN102670485B (en) | Method for researching and controlling hydrolysis impurity H in solid composition containing valsartan | |
| CN110420192B (en) | Isosorbide mononitrate sustained-release tablet and preparation method thereof | |
| CN103142494B (en) | Ornidazole oral preparation and preparation method thereof | |
| CN104490835B (en) | A kind of Azilsartan tablet and preparation method thereof | |
| CN106606494A (en) | Pimavanserin pharmaceutical composition and preparation method thereof | |
| CN103435496B (en) | Bromhexine hydrochloride compound, and preparation method, medicinal composition and preparation thereof | |
| CN104188927B (en) | A kind of Mosapride Citrate Tablets agent and preparation method thereof | |
| CN102302466A (en) | Capecitabine medicinal composition capable of direct powder tableting, and application thereof | |
| CN105395506B (en) | A kind of clonidine hydrochloride sustained release tablets | |
| CN104840427A (en) | Pharmaceutical composition containing montelukast sodium | |
| CN105641680A (en) | Oritavancin pharmaceutical composition and preparation method thereof | |
| CN105640936A (en) | Eribulin mesylate pharmaceutical composition and preparation method | |
| CN103989643B (en) | Tablet containing ramelteon and copolyvidone | |
| CN103536578B (en) | A kind of Cefixime Capsules and preparation method thereof | |
| CN105640912A (en) | Carfilzomib pharmaceutical composition and preparation method thereof | |
| CN105640914A (en) | Levomilnacipran pharmaceutical composition and preparation method thereof | |
| CN110613694A (en) | Pregabalin capsule and preparation method thereof | |
| CN101721416B (en) | Huperzine A solid composition and preparation method thereof | |
| CN106606493A (en) | Tofacitinib medicine composite and preparation method thereof | |
| CN103989680A (en) | Pharmaceutical composition containing ptavastatin calcium | |
| CN106822026A (en) | A kind of new amoxil capsule | |
| CN105769853A (en) | Vildagliptin pharmaceutical composition | |
| CN105640977A (en) | Telithromycin medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160608 |